ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 40 (3) , 301-307
- https://doi.org/10.1016/s0169-5002(03)00079-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy VolunteersClinical Pharmacokinetics, 2001
- Kinase Inhibitors in Cancer TherapyDrugs, 2000
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and AktMolecular and Cellular Biology, 1997
- A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancerEuropean Journal Of Cancer, 1996
- Assessment of Quality-of-Life OutcomesNew England Journal of Medicine, 1996
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)European Journal Of Cancer, 1993